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Progressive renal vascular sclerosis is a key feature of chronic
kidney disease (CKD). Adiponectin, an adipokine with potent
anti-inflammatory and antiatherosclerotic properties, is
associated with insulin resistance, type II diabetes and
cardiovascular disease. In this study, we evaluated the
predictive value of adiponectin for the progression of CKD in
patients enrolled in the Mild to Moderate Kidney Disease
Study. The primary end point was defined as a doubling of
the baseline serum creatinine and/or terminal renal failure in
177 patients who completed a prospective follow-up of 7
years. Patients who reached a progression endpoint (n¼ 65)
were significantly older, had higher baseline serum
creatinine, proteinuria and adiponectin concentrations
and more components of the metabolic syndrome.
A gender-stratified Cox model revealed adiponectin in men
as a significant predictor of progression after adjustment
for age, glomerular filtration rate, and proteinuria. Male
patients with adiponectin levels above their ROC
analysis-derived optimal cutoff of 4 lg/ml had a significantly
faster progression than patients below this point. This
prospective long-term study in patients with CKD
indicates high adiponectin as a novel independent
predictor of disease progression in men but not in
women. Our observation may be relevant for other
conditions of progressive vascular sclerosis and diabetic
nephropathy.
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The kidney contains a vast amount of vessels of different size
and function with an enormous endothelial surface. As a
consequence, pathophysiological conditions involving the
vascular bed are not only related to atherosclerotic changes of
major vessels of the heart and the brain, but also to vascular
changes within the kidney. It has been even proposed that
glomerulosclerosis and atherosclerosis share common patho-
physiological pathways.1 However, little is known about the
exact mechanisms,2 and factors related to atherosclerosis as
well as glomerular–endothelial injury might be interesting
candidates to be involved in the progression of kidney disease.
One of these putative candidates is adiponectin, the major
adipocyte-secretory protein. It has been demonstrated to
improve insulin sensitivity and to possess anti-inflammatory
and antiatherosclerotic properties.3 Hypoadiponectinaemia
has been found to be associated with insulin resistance,4,5
obesity, and other features of the metabolic syndrome6 as well
as type II diabetes mellitus and cardiovascular disease.7–9
Recent data suggested that the presence of a metabolic
syndrome might be a causal factor for chronic kidney disease
(CKD).10,11 In addition, we observed that insulin resistance is
present already in patients with mild degrees of renal
impairment and even in patients with primary CKD and
normal glomerular filtration rate (GFR).12 Because of the
relationship between adiponectin and the metabolic syn-
drome, we decided to investigate the predictive value of
adiponectin for progression in a prospective 7-year follow-up
study in a cohort of non-diabetic patients with mostly mild
to moderate primary CKD.
RESULTS
Baseline characteristics
A total of 177 patients (78%) from the baseline cohort could
be assessed during the follow-up. The remaining 50 patients
lost to follow-up had moved away and/or did not return for
another visit in the outpatients departments. They had a
significantly better kidney function than those who came to
follow-up examinations: GFR 91 vs 64 ml/min/1.73 m2,
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serum creatinine 1.55 vs 2.15 mg/dl, proteinuria 0.6 vs
1.0 g/24 h. Only 12 of those 50 patients (24%) were in the
GFR groups 1–3 (GFR below 60 ml/min/1.73 m2) compared with
94 of 177 patients with follow-up (53%). They had also lower
adiponectin levels (5.3 vs 6.3 mg/ml) and higher hemoglobin
levels (14.4 vs 13.6). They tended to have a lower number of
metabolic syndrome components (2.24 vs 2.43) but both
groups did not differ significantly with respect to age and sex.
Baseline clinical characteristics and laboratory data of the
patients with follow-up are reported in the first column of
Table 1. Table 2 shows the correlations of adiponectin, age,
GFR, proteinuria with the various components of the
metabolic syndrome. During follow-up, 65 patients pro-
gressed to a renal end point, which was terminal renal failure
requiring renal replacement therapy in 29 patients and
doubling of baseline serum creatinine without reaching end-
stage renal disease in 36 patients. Table 1 further presents
data of patients with and without disease progression.
Patients who had reached a progression end point were
significantly older, had higher baseline serum creatinine, and
adiponectin levels and protein excretion rates as well as lower
GFR. In addition, more components of the metabolic
syndrome were present in these patients (Po0.005). There
were no significant differences between men and women
either in the time of observation until the primary study end
point or the end of the observation period was reached
(48.9719.7 vs 44.5719.1 months, P¼ 0.21) nor the
frequency of progression (37 vs 36%, P¼ 0.83).
Adiponectin as a predictor of kidney disease progression
Age- and sex-adjusted Cox regression analysis revealed high
adiponectin levels as a significant predictor of disease
progression (Table 3). A metabolic syndrome was not a
significant predictor for disease progression (P¼ 0.32).
However, when the singular components of the metabolic
syndrome were tested in the Cox regression analysis, we
found triglycerides and high-density lipoprotein cholesterol
levels to be related to the progression of disease. An
interaction term between adiponectin concentrations and
sex was highly significant (P¼ 0.001). Therefore, all further
analyses were stratified for men and women.
In women, adiponectin concentrations were not a
significant predictor in either model. On the contrary, in
men adiponectin was a significant predictor of disease
progression in all models adjusting for age alone or
additionally adjusting for GFR, proteinuria, metabolic
Table 1 | Baseline clinical and laboratory data of 177 patients who completed follow-up with further stratification into those
without and with progression of kidney disease during the follow-up period
All patients (n=177) Non-progressors (n=112) Progressors (n=65)
Sex (male/female), n (%) 118/59 (67/33%) 74/38 (66/34%) 44/21 (68/32%)
Age (years) 46.4712.2 44.8712.6 49.1711.1*
Follow-up time (years)a 47720 55716 34718****
(32; 53; 63) (52; 59; 66) (18; 34; 46)
BMI (kg/m2) 25.273.7 24.873.5 25.773.9
Current smokers, n (%) 34 (19%) 18 (16%) 16 (25%)
Systolic blood pressure (mm Hg) 137720 136722 137717
Diastolic blood pressure (mm Hg) 87713 86714 88712
Blood pressure medication, n (%) 143 (81%) 82 (73%) 61 (94%)***
Serum creatinine (mg/dl) 2.1571.22 1.5470.61 3.2171.31****
Glomerular filtration rate (ml/min/1.73 m2) 64739 79738 38725****
(35; 54; 89) (50; 74; 99) (20; 33; 46)
Proteinuria (g/24 h/1.73 m2) 1.0170.92 0.8770.95 1.2570.83****
(0.20; 0.70; 1.63) (0.14; 0.46; 1.25) (0.61; 1.09; 1.78)
Serum albumin (g/dl) 4.5670.40 4.5770.43 4.5370.36
High-sensitivity C-reactive protein (mg/l) 0.2870.31 0.2870.32 0.2970.31
Adiponectin (mg/ml) 6.3174.43 5.8974.27 7.0574.63*
(3.43; 5.04; 7.73) (2.93; 4.60; 7.34) (4.10; 5.49; 8.61)
Metabolic syndrome, n (%)b 85 (48%) 47 (42%) 38 (59%)*
Metabolic factors, nc 2.4371.17 2.2571.21 2.7471.02***
Insulin (mU/l) 13.5079.70 13.72711.14 13.1176.61
Triglycerides (mg/dl) 172795 159793 194796***
(104; 144; 223) (97; 131; 201) (121; 181; 244)
HDL cholesterol (mg/dl) 44715 46715 40713**
Glucose (mg/dl) 98715 99716 97714
Use of fibrates, n (%) 9 (5%) 6 (5%) 3 (5%)
BMI, body mass index; HDL, high-density lipoprotein.
Data are provided as mean7s.d. (25th, 50th, 75th percentile where appropriate) or n (%).
*Po0.05; **Po0.01; ***Po0.005; ****Po0.001 – comparison between progressors and non-progressors.
aFollow-up time was calculated as the time from enrollment until the primary study end point or the end of the observation period was reached.
bDefinition according to the scientific statement from the American Heart Association and the National Heart, Lung, and Blood Institute. Three of the following five
parameters had to be present: elevated triglycerides X150 mg/dl (1.7 mmol/l) or on drug treatment for elevated triglycerides, reduced HDL-cholesterol o40 mg/dl
(1.03 mmol/l) in men,o50 mg/dl (1.3 mmol/l) in women or on drug treatment for reduced HDL-cholesterol, hypertension:X130 mm Hg systolic blood pressure or X85 mm
Hg diastolic blood pressure or on antihypertensive drug treatment in a patient with a history of hypertension, elevated fasting glucose:X100 mg/dl or on drug treatment for
elevated glucose; as waist circumference was not available in our cohort we used BMI430 kg/m2.
cMetabolic factors: average number of factors considered in the definition of metabolic syndrome (see footnote above).
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syndrome, or singular components of the metabolic syn-
drome (Po0.0001) (Table 4). The estimates for adiponectin
were very stable and independent for the component of the
metabolic syndrome adjusted (Table 4). Adiponectin levels
were still significantly associated with disease progression in
men even when adjusted for asymmetric dimethylarginine or
apolipoprotein A-IV, which we recently showed to be
significant predictors of progression.13,14 The same holds
true for the type of renal disease as well as the use or kind of
antihypertensive medications when adjusted for baseline GFR
(data not shown). We further observed that male patients in
the lowest compared with the highest tertile of body mass
index (BMI) showed a clear trend to higher adiponectin
levels (6.5574.30 vs 5.3174.52 mg/ml, P¼ 0.098) and a
higher probability of disease progression (hazard ratio (HR)
(95% CI) 2.46 (1.03–5.89), P¼ 0.043).
Separately for men and women, we constructed Kaplan–
Meier curves of the progression-free period comparing
patients with high versus low serum adiponectin concentra-
tions using the sex-specific optimal cutoff. This optimal
cutoff was derived from receiver operating characteristics
analysis and refers to the value, which optimizes sensitivity
and false positive rates for the study outcome and was
4 mg/ml for both sexes. Male patients with adiponectin levels
above this threshold had a worse prognosis and significantly
faster progression to the end point compared with those with
adiponectin levels below this threshold (log-rank test,
P¼ 0.0005) (Figure 1): the mean follow-up time to progres-
sion was 54.9 (95% CI: 47.8–62.0) months compared with
73.2 (95% CI 67.8–78.6) months, respectively. In women,
there was no evidence for a difference in progression-free
period in relation to the adiponectin level.
Additional analyses
When Cox regression analysis was performed for both end
points separately, adiponectin was a highly significant
Table 2 | Spearman correlation coefficients of adiponectin, age, GFR, proteinuria, and the various components of the metabolic
syndrome stratified for men (left lower triangle, n=118) and women (right upper triangle, n=59)
Age Adiponectin GFR Proteinuria BMI Triglycerides HDL cholesterol Glucose Hypertension
Age — 0.17 0.53**** 0.21 0.38*** 0.20 0.09 0.21 0.31*
Adiponectin 0.10 — 0.09 0.05 0.17 0.02 0.20 0.02 0.04
GFR 0.24* 0.26** — 0.17 0.31* 0.36** 0.11 0.15 0.33*
Proteinuria 0.06 0.14 0.20* — 0.05 0.14 0.03 0.01 0.11
BMI 0.40**** 0.10 0.12 0.01 — 0.25 0.15 0.32* 0.37***
Triglycerides 0.16 0.09 0.25** 0.08 0.23* — 0.36** 0.08 0.16
HDL cholesterol 0.02 0.26** 0.18* 0.10 0.14 0.48**** — 0.02 0.06
Glucose 0.17 0.13 0.12 0.04 0.32*** 0.19* 0.05 — 0.21
Hypertension 0.32**** 0.05 0.24** 0.11 0.19* 0.16 0.03 0.07 —
Correlations of the right upper triangle are those of women (n=59) and those of the left lower triangle are those of men (n=118).
BMI, body mass index; GFR, glomerular filtration rate; HDL, high-density lipoprotein.
*Po0.05, **Po0.01, ***Po0.005, ****Po0.001.
Table 3 | Association of different variables with progression of kidney disease during the observation period using age- and
sex-adjusted Cox proportional hazards regression models
Entire group
Variable (increment)
HR per unit increment (95% CI)
adjusted for age and sex P
GFR (10 ml/min/1.73 m2) 0.67 (0.59–0.76) o0.0001
Proteinuria (1 g/24 h/1.73 m2) 1.30 (1.02–1.65) 0.032
Adiponectin (1mg/ml) 1.08 (1.02–1.15) 0.005
Adiponectin X4 mg/ml 2.53 (1.32–4.85) 0.01
Metabolic syndrome (1=yes, 0=no) 1.32 (0.77–2.27) 0.32
Single components of metabolic syndrome
Hypertension (1=yes, 0=no)a 4.94 (0.66–36.99) 0.12
BMI (1 kg/m2) 1.01 (0.94–1.09) 0.73
BMI 430 kg/m2 (1=yes, 0=no)a 0.83 (0.35–1.95) 0.67
Triglycerides (1 mg/dl) 1.002 (0.999–1.004) 0.21
Triglycerides X150 mg/dl (1=yes, 0=no)a 1.86 (1.09–3.18) 0.02
HDL cholesterol (1 mg/dl) 0.977 (0.956–0.998) 0.03
HDL cholesterol o40/o50 mg/dl for men and women, respectively (1=yes, 0=no)a 1.41 (0.83–2.38) 0.21
Glucose (1 mg/dl) 0.99 (0.97–1.01) 0.16
Glucose X100 mg/dl (1=yes, 0=no)a 0.75 (0.43–1.29) 0.29
BMI, body mass index; CI, confidence interval; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HR, hazards ratio.
aDichotomization of these parameters included in the definition of the metabolic syndrome was performed according to the scientific statement from the American Heart
Association and the National Heart, Lung, and Blood Institute.
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predictor for reaching terminal renal failure (HR 1.21, 95%
CI 1.11–1.32, Po0.001) and a tendency towards an increased
HR for doubling of serum creatinine (HR 1.09, 95% CI
0.98–1.22, P¼ 0.11) in men. Adiponectin was not predictive
for either of the end points in women.
Regarding sex differences in the baseline variables it
should be noted that adiponectin levels were significantly
different between men and women (5.6474.22 vs
7.6674.58 mg/ml, P¼ 0.004). Men suffered more often from
a metabolic syndrome (56 vs 32%, P¼ 0.003) and had
significantly more components of the metabolic syndrome
compared with women (2.6771.14 vs 1.9571.07, Po0.001)
(Figure 2). These included a significantly higher prevalence of
low high-density lipoprotein cholesterol (64 vs 39%,
P¼ 0.002), high triglyceride (56 vs 39%, P¼ 0.034), and
high glucose levels (45 vs 19%, P¼ 0.001) in men compared
with women.
DISCUSSION
Recent cross-sectional studies showed impaired kidney
function to be associated with increased adiponectin
levels.5,12,15 Potential mechanistic explanations are changes
in the ligand/receptor reactivity as shown for other hormone/
receptor systems in renal failure,16 reduced adiponectin
clearance by the kidney,17 or a counter-regulatory response to
metabolic derangements in renal failure.18 Therefore, kidney
function seems to be an important determinant of adipo-
nectin levels. However, prospective studies investigating
whether adiponectin levels serve as a predictor of CKD
progression are missing. Our prospective study in patients
with non-diabetic primary CKD identified high adiponectin
levels as a novel predictor of CKD progression in men, but
not in women, independent of other predictors of disease
progression.
Controversy in the literature: is the association to be
reshaped?
Considering the bulk of the literature, the finding of high
adiponectin levels as predictor of CKD progression, at least in
men, was unanticipated considering that low rather than
high adiponectin levels were reported to be associated with
obesity, type II diabetes mellitus, and cardiovascular disease
in the general population. In contrast to these cross-sectional
findings some,19–24 but not all,7–9,24 prospective studies failed
to document an association between low adiponectin levels
and cardiovascular events. Studies in selected groups of
patients with various diseases at baseline showed even
associations of high adiponectin levels with various out-
comes. An investigation in type I diabetes patients found
increased concentrations of adiponectin and a positive
association with soluble vascular cell adhesion molecule-1
that is a marker of generalized vascular dysfunction.25 The
Ludwigshafen Risk and Cardiovascular Health Study inves-
tigated almost 2500 patients with coronary artery disease at
baseline and followed them for more than 5 years. Increased
adiponectin levels were strongly associated with all-cause and
cardiovascular mortality.26 Similar results were reported by
the Modification of Diet in Renal Disease study in patients
with a mean GFR of 33 ml/min/1.73 m2.27 Recently, in the
study of Kistorp et al.,28 high adiponectin levels were
predictive for mortality in patients with chronic heart failure
(CHF), independent of CHF severity. It has recently been
suggested that adiponectin increases energy expenditure and
induces weight loss through a direct effect on the brain.29 It
has been proposed that in the context of increased energy
expenditure high plasma adiponectin levels might not be
beneficial in CHF. And the same is potentially true in renal
patients. This would be in line with our observation that
male patients in the lowest tertile of BMI had higher
Table 4 | Association of adiponectin with progression of kidney disease during the observation period using various adjusted
Cox proportional hazards regression models stratified by sex
Stratified by sex
Women Men
Adjusted for
HR (95% CI) of disease
progression per 1 lg/ml
increment of adiponectin P
HR (95% CI) of disease
progression per 1 lg/ml
increment of adiponectin P
Age, GFR 0.98 (0.83–1.16) 0.83 1.16 (1.09–1.24) o0.0001
Age, GFR, proteinuria 0.96 (0.81–1.13) 0.61 1.16 (1.08–1.23) o0.0001
Age, GFR, proteinuria, HDL-C 0.96 (0.82–1.13) 0.61 1.16 (1.09–1.24) o0.0001
Age, GFR, proteinuria, BMI 0.96 (0.81–1.13) 0.61 1.16 (1.08–1.24) o0.0001
Age, GFR, proteinuria, triglycerides 0.93 (0.78–1.11) 0.45 1.16 (1.09–1.24) o0.0001
Age, GFR, proteinuria, hypertension 0.96 (0.81–1.13) 0.60 1.15 (1.08–1.23) o0.0001
Age, GFR, proteinuria, HOMA-IR 0.93 (0.79–1.11) 0.44 1.15 (1.08–1.22) o0.0001
Age, GFR, proteinuria, metabolic syndrome 0.96 (0.81–1.13) 0.62 1.16 (1.08–1.23) o0.0001
Adjusted for
HR (95% CI) of disease
progression for adiponectin
X4 lg/ml P
HR (95% CI) of disease
progression for adiponectin
X4 lg/ml P
Age, GFR 0.71 (0.18–2.80) 0.63 2.27 (1.07–4.80) 0.03
Age, GFR, proteinuria 0.57 (0.14–2.36) 0.44 2.28 (1.08–4.80) 0.03
CI, confidence interval; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HR, hazards ratio; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance.
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adiponectin levels and were more likely to progress. In this
respect, CHF and CKD patients may have much in common
and many traditional risk factors such as hypercholestrole-
mia, hypertension, or high BMI may provide beneficial
outcomes, a well known constellation which is called ‘reverse
epidemiology’.30 Taken together, from studies in patients with
type I diabetes mellitus, pre-existing coronary artery disease,
CHF as well as in patients with CKD, it might be concluded
that the well known association of low adiponectin levels
with adverse outcome in the general population is not
necessarily valid in patients with severe and chronic disease
and probably even turns into the opposite direction. It is
conceivable that the upregulation of adiponectin is a
compensatory attempt to attenuate endothelial and vascular
damage as recently suggested.25
Adiponectin resistance as an alternative explanation
An alternative explanation for the association of high
adiponectin levels with progression of CKD in men could
be adiponectin resistance31,32 caused by a dysfunction of
adiponectin itself or a dysfunction or downregulation of
adiponectin receptors with consecutive counter-regulatory
increased adiponectin secretion. Such adiponectin resistance
might be analogous to the finding of the virtually absent
uptake of adiponectin across the coronary bed found in
diabetic compared with non-diabetic patients.32 It is also in
accordance with major post-translational modifications of
adiponectin caused by glycosylation as observed recently.33
As advanced glycation products as well as the frequency of
components of the metabolic syndrome are increased in
kidney disease, resulting alterations of the adiponectin
molecule might be an intriguing hypothesis which could
explain the paradox phenomenon of high adiponectin levels
with CKD progression.
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Figure 1 | Kaplan–Meier curves of renal end points in male (upper
panel) and female (lower panel) patients with plasma
adiponectin concentrations above and below the sex-specific
cutoff of 4 lg/ml. This most useful cutoff value of adiponectin for
predicting disease progression was derived from receiver operating
characteristics analysis. At this value, the greatest sum of sensitivity
and specificity was obtained. Male patients with adiponectin levels
above the cut-point showed a significantly faster progression than
those below this value (log-rank test, P¼ 0.0005). No significant
difference was observed in women (P¼ 0.92). Each small tick line at
the survival curves indicates censoring of a patient. Numbers near the
survival curves represent the number of patients at risk with plasma
adiponectin levels below and above the cut-off at the times 0, 12, 24,
36, 48, 60, and 72 months. Consider that a disease progression in one
patient close to the end of the observation period when only few
patients are still at risk has a dramatic impact on the decline of the
curve, which has to be interpreted with caution.
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Figure 2 | Frequency of patients according to the concomitant
number of components of the metabolic syndrome stratified by
sex. In male patients, significantly more components of the
metabolic syndrome were present as compared with women
(Mantel–Haenszel test: w2¼ 15.0, df¼ 1, P¼ 0.0001). The factors
considered in this analysis are listed in the footnote of Table 1.
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Kidney functional considerations
The observed association of adiponectin and CKD progres-
sion, however, could also reflect a functional impairment of
the kidney, which is less related to diminished glomerular
filtration (and which we considered already by measuring
and adjusting for GFR) than to other non-filtration-related
consequences of kidney dysfunction; or in other words, a
residual confounding of kidney function not related to GFR.
Sex differences
Adiponectin levels were not predictive for CKD progression
in women although women have significantly higher
adiponectin levels compared with men. An explanation for
this finding might again be the presence of adiponectin
resistance, which could be more pronounced in men than in
women. This assumption is in line with the observation that
in our cohort of women a metabolic syndrome was less
frequent and the number of components of the metabolic
syndrome was lower compared with men, which was mainly
the case for the lipid and glucose components. This finding is
different from the general population in which the metabolic
syndrome tends to be more frequent in women.34 We
speculate that the ligand–receptor interaction might be less
disturbed in women compared with men, which could be due
to less functionally impaired adiponectin molecules in
women as discussed above. It is of interest in this context
that in a recent study in 839 children aged 8 years,
adiponectin levels were associated with body weight, BMI,
waist circumference, and fasting and 30-min insulin levels,
but the associations were opposite in boys, with positive
associations, and girls, with inverse associations.35 Whether a
complex age- and sex-related regulation of adiponectin
metabolism with possible functional consequences plays a
role in adults has to be investigated in upcoming studies.
Data in mice showing that females have not only higher levels
of adiponectin but also increased proportions of the high-
molecular weight complexes.36 Therefore, different adipo-
nectin bioactivity could be an explanation for the sex-specific
findings.
Limitations of the study
One study limitation is the fact that we did not assess waist
circumference according to the American Heart Association
(AHA) and National Heart, Lung, and Blood Institute
(NHLBI) criteria for clinical diagnosis of the metabolic
syndrome. Instead, we used obesity defined by BMI430 kg/m2
to consider the obesity component of the metabolic
syndrome. However, as recent discussions doubted the
common pathogenetic roots of this syndrome37 we have
put more emphasis on adiponectin and the singular
components of the metabolic syndrome.
Another limitation is that we have no clinical data on
CHF. Further, the applied exclusion criteria in our study (e.g.,
diabetic nephropathy or age465 years) resulted in a selected
group of patients and our findings may therefore not be
applicable to other types of CKD such as diabetic nephro-
pathy or to other ethnicities. However, a recent case–control
study in type I diabetic patients found a significant
association of the A-allele of the adiponectin-promoter single
nucleotide polymorphism rs17300539 with diabetic nephro-
pathy.38 A systematic investigation of the adiponectin gene
found this single nucleotide polymorphism to be strongly
associated with adiponectin concentrations with about 20%
higher adiponectin levels in carriers of the A allele.39 Our
observation of high adiponectin levels with progression of
primary CKD is in line and extends the association of the A
allele and its higher adiponectin levels with diabetic
nephropathy.
To test the confounding effect of relevant risk factors on
the predictive power of adiponectin on CKD progression, the
multiple Cox regression analysis might be underpowered in
women. However, even models that included only GFR and
adiponectin with and without age were far away from any
significance.
Finally, it might be considered a limitation that we do not
have follow-up data on 50 (22%) patients of the baseline
cohort. However, as these patients had a far better kidney
function at baseline than the patients under prospective
observation, we assume that most of them remained stable
without symptoms over years and therefore no more visited
the outpatient ward. A survival bias might be excluded
considering this far better kidney function and the fact that
even in the patients under prospective observation only three
out of 177 patients died, which might be explained by the
relatively low average age of 46 years at study entry and the
regular care by nephrologists. Nevertheless, we additionally
performed two simulation analyses adding each of these 50
patients to the followed 177 patients once as progressor and
once as non-progressor. Both simulations resulted still in
significant associations for adiponectin in men, which were
more pronounced in the second simulation (data not shown).
In summary, in our prospective study with 7 years of
follow-up in patients with non-diabetic CKD, we identified
adiponectin as a novel predictor for CKD progression in men
but not in women. This observation may be of relevance for
other conditions of progressive vascular sclerosis as well as
for patients with diabetic nephropathy.
MATERIALS AND METHODS
Patients and baseline investigations
We examined 227 Caucasian patients aged between 18 and 65 years
with non-diabetic CKD and various degrees of renal impairment.
They were recruited from eight nephrology departments in
Germany, Austria, and South Tyrol by one physician who visited
all participating centers as described earlier.14,40 The study was
approved by the institutional ethic committees and subjects gave
written informed consent. Patients had stable renal function for at
least 3 months before entry into the study. Exclusion criteria were
treatment with immunosuppressive agents, fish oil or erythropoie-
tin, serum creatinine above 6 mg/dl, diabetes mellitus of any type,
malignancy, liver, thyroid or infectious disease, nephrotic syndrome
(defined as proteinuria 43.5 g/1.73 m2/day), organ transplantation,
allergy to ionic contrast media, and pregnancy. Patient history,
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including smoking habits and antihypertensive treatment, was
recorded by interview and confirmed by checking patient records.
This was complemented by clinical examination including assess-
ment of BMI, blood glucose, and blood pressure. Diagnosis of
diabetes mellitus of any kind was based on several measurements of
fasting blood glucose.
The primary cause of CKD was glomerulonephritis in 97
(biopsy-confirmed in 90) patients, adult polycystic kidney disease
in 37 patients, interstitial nephritis in 24 patients, other types of
kidney disease in 43 patients, and unknown in 26 patients.
Prospective follow-up and definition of renal end points
After the baseline investigation, patients were followed prospectively
until the primary study end point or the end of the observation
period was reached. The primary end point was defined as doubling
of baseline serum creatinine and/or terminal renal failure necessitat-
ing renal replacement therapy.
Laboratory measurements
Blood samples for the measurement of adiponectin and other
parameters were taken after an overnight fast of at least 12 h.
Adiponectin plasma concentrations were measured with an enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis, MN,
USA). GFR was assessed in all patients using the iohexol clearance
technique as described in detail elsewhere.41 Criteria for clinical
diagnosis of metabolic syndrome were defined according to the
scientific statement from the AHA and the NHLBI.42 We have also
quantified insulin sensitivity in our patients using the Homeostasis
Model Assessment of Insulin Resistance: plasma insulin (mU/l)
plasma glucose (mg/dl)405.
Statistical analysis
Comparisons of variables between various groups were performed
using unpaired t-tests, nonparametric Wilcoxon rank sum tests and
Pearson’s w2 test. The HRs for CKD progression were estimated
using a Cox proportional hazards regression model adjusted for age
and other risk factors of disease progression. To consider the
possibility of a nonlinear association between continuous variables
of metabolic syndrome components (BMI, triglycerides, high-
density lipoprotein cholesterol) with progression-free period, the
analysis was also performed using categorical variables using
the cutoff, which defines each of those components (defined in
the footnote to Table 1). Finally, we tested for multicollinearity and
fulfillment of proportional hazard assumptions.
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